Oral Oncology Reports最新文献_第8页

Insulin receptor substrate 1 (IRS 1) serum levels in patients with Oral Squamous Cell Carcinoma 口腔鳞状细胞癌患者血清胰岛素受体底物1 （IRS 1）水平

Oral Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-01-03 DOI: 10.1016/j.oor.2024.100708

Deeksheetha Prabhuvenkatesh , Karthikeyan Ramalingam , Pratibha Ramani , Selvaraj Jayaram

{"title":"Insulin receptor substrate 1 (IRS 1) serum levels in patients with Oral Squamous Cell Carcinoma","authors":"Deeksheetha Prabhuvenkatesh , Karthikeyan Ramalingam , Pratibha Ramani , Selvaraj Jayaram","doi":"10.1016/j.oor.2024.100708","DOIUrl":"10.1016/j.oor.2024.100708","url":null,"abstract":"<div><h3>Aim</h3><div>To assess the expression of IRS 1 values in Oral Squamous Cell Carcinoma (OSCC) patients and its association with histological grading, tumor staging, and habits.</div></div><div><h3>Objective</h3><div>To assess the expression of IRS1 in patients with oral squamous cell carcinoma. To correlate IRS1 values with histological grading, tumor staging, habits, and overall survival in OSCC patients.</div></div><div><h3>Materials and methods</h3><div>IRS 1 values were assessed in N = 106 patients. IRS 1 values in 53 OSCC patients at preoperative and postoperative 3 months and were compared with 53 healthy controls using the sandwich ELISA method. The IRS 1 values were associated with clinicohistopathological factors. Statistical analysis was carried out using SPSS version 23.0 by IBM. One-way ANOVA and paired student t-tests were carried out and any p-value less than 0.05 was considered significant.</div></div><div><h3>Results</h3><div>The mean preoperative IRS 1 value in OSCC patients was 0.071 <em>±</em> 0.013, (p-value <0.001) and the mean postoperative 3 months IRS 1 value was 0.103 <em>±</em> 0.037 (p-value = 0.025). The mean IRS 1 value of healthy controls was 0.134 <em>±</em> 0.111 (p-value <0.001). The mean values in preoperative OSCC patients were underexpressed, compared to healthy controls and postoperative OSCC patients.</div></div><div><h3>Conclusion</h3><div>IRS1 expression was associated with various clinicopathological factors such as habit status, pathological tumor staging, and tumor grading. It was also found that underexpression of IRS1 was associated with poor prognosis of OSCC patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100708"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiological and clinical differential diagnostics of CPPD in the temporomandibular joint extending into the cranium: Insights from the literature and a rare clinical case 颞下颌关节延伸至颅骨的CPPD的放射学和临床鉴别诊断：来自文献和罕见临床病例的见解

Oral Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-03 DOI: 10.1016/j.oor.2025.100716

Anne-Laure Vandevelde , Maarten Verbist , Jonas Ver Berne , Joris Geusens , Steven De Vleeschouwer , Reinhilde Jacobs , Robin Willaert , Michel Bila

{"title":"Radiological and clinical differential diagnostics of CPPD in the temporomandibular joint extending into the cranium: Insights from the literature and a rare clinical case","authors":"Anne-Laure Vandevelde , Maarten Verbist , Jonas Ver Berne , Joris Geusens , Steven De Vleeschouwer , Reinhilde Jacobs , Robin Willaert , Michel Bila","doi":"10.1016/j.oor.2025.100716","DOIUrl":"10.1016/j.oor.2025.100716","url":null,"abstract":"<div><div>Calcium pyrophosphate deposition disease (CPPD) in the temporomandibular joint (TMJ) is rare but occasionally appears locally destructive. Various radiological techniques are available for differential diagnosis. We present the case of a 66-year-old man with long-standing, painful, unilateral TMJ swelling. Radiological imaging showed a mass with calcifications, erosion of the articular roof and invasion of the middle cranial fossa. Differential diagnoses included CPPD, tenosynovial giant cell tumor, synovial chondromatosis, chondrosarcoma, and osteochondroma. A biopsy confirmed CPPD, followed by resection of the lesion and immediate TMJ reconstruction with a patient-specific prosthesis. Benign and malignant TMJ lesions extending into the cranium are uncommon and their radiological differentiation remains challenging. Therefore, we performed a scoping review focusing on TMJ imaging allowing differential diagnosis of CPPD.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100716"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143403078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of spindle cell squamous cell carcinoma of the tongue complicated by verrucous carcinoma 舌梭形细胞鳞状细胞癌合并疣状癌1例

Oral Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-02 DOI: 10.1016/j.oor.2025.100719

Yusuke Matsuzaki, Daiki Saito, Saimon Yasuhara, Yukio Watabe, Shiro Shigematsu

引用次数: 0

Re-irradiation with concurrent pembrolizumab for local-regionally recurrent squamous cell carcinoma of the head and neck 再照射并发派姆单抗治疗局部复发的头颈部鳞状细胞癌

Oral Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-05 DOI: 10.1016/j.oor.2025.100714

Allen M. Chen , Jeremy P. Harris , Rupali Nabar , Tjoson Tjoa , Yarah Haidar , William B. Armstrong

{"title":"Re-irradiation with concurrent pembrolizumab for local-regionally recurrent squamous cell carcinoma of the head and neck","authors":"Allen M. Chen , Jeremy P. Harris , Rupali Nabar , Tjoson Tjoa , Yarah Haidar , William B. Armstrong","doi":"10.1016/j.oor.2025.100714","DOIUrl":"10.1016/j.oor.2025.100714","url":null,"abstract":"<div><h3>Purpose</h3><div>To report a single institutional experience with re-irradiation and concurrent pembrolizumab for local-regionally recurrent squamous cell carcinoma of the head and neck.</div></div><div><h3>Method and materials</h3><div>A total of 16 patients were treated with external-beam re-irradiation to median dose of 66 Gy with concurrent pembrolizumab for histologically confirmed local-regionally recurrent squamous cell carcinoma of the head and neck. All patients had measurable disease. Twelve (75 %) were male and four (25 %) were female. The median age at the time of recurrence was 56 years (range, 42–80 years). The median interval from completion of prior radiation to recurrent disease was 28 months (range, 6–50 months). Nine patients (56 %) were p16 positive; 7 patients (44 %) were p16 negative.</div></div><div><h3>Results</h3><div>With a median follow-up time of 20 months, the 1- and 2-year estimates of overall survival were 71 % and 56 %, respectively. Of the 16 patients who underwent re-irradiation, eleven (69 %) had a complete response and 3 (19 %) had a partial response. Two patients (13 %) had stable disease after re-irradiation, and none progressed during treatment. A total of 6 patients developed metastasis outside of the re-irradiated area. The 1- and 2-year estimates of progression-free survival were 61 % and 37 %, respectively. The prevalence of acute and late grade 3+ toxicity was 25 % and 19 %, respectively.</div></div><div><h3>Conclusion</h3><div>Re-irradiation with pembrolizumab for patients with recurrent squamous cell carcinoma of the head and neck is safe and potentially effective. A prospective study is under development to better identify who might benefit the most from this approach.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100714"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral toxicities associated with immunotherapy and targeted therapy in cancer treatment 在癌症治疗中与免疫治疗和靶向治疗相关的口服毒性

Oral Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-07 DOI: 10.1016/j.oor.2025.100724

Michel Souza Sueira , Juliana Borges de Lima Dantas , Gabriela Botelho Martins , Daniela Maria Santana Leal , Juliana Santos de Jesus Azevedo , Manoela Carrera

引用次数: 0

Oligometastatic squamous cell carcinoma treated with and without involved site radiation 少转移性鳞状细胞癌有或没有受累部位放射治疗

Oral Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-01-09 DOI: 10.1016/j.oor.2024.100707

Allen M. Chen

{"title":"Oligometastatic squamous cell carcinoma treated with and without involved site radiation","authors":"Allen M. Chen","doi":"10.1016/j.oor.2024.100707","DOIUrl":"10.1016/j.oor.2024.100707","url":null,"abstract":"<div><h3>Purpose</h3><div>Comprising a heterogenous population, the optimal management of oligometastatic head and neck cancer is uncertain. We sought to report outcomes among patients treated with and without stereotactic body radiotherapy (SBRT) to local sites of disease.</div></div><div><h3>Methods and materials</h3><div>A review of institutional registries identified 49 patients with metastatic squamous cell carcinoma of the head and neck limited to 5 sites of disease or less. Patients with intact disease at primary local-regional sites; those treated by palliative radiation; and those who had previously received first-line systemic therapy were excluded.</div></div><div><h3>Results</h3><div>A total of 20 patients met eligibility criteria. Treatment included systemic therapy alone (10 patients) and systemic therapy with SBRT (10 patients). The median progression-free survival was 11 months and 6 months, respectively (p = 0.09). The 2-year overall survival was 29 % and 15 % for patients treated by SBRT and systemic therapy compared to systemic therapy alone, respectively (p = 0.21). There were no differences in the development of grade 3+ toxicity between the 2 groups, with the incidence of grade 3+ toxicity being 20 % and 30 % for patients treated with and without SBRT, respectively (p = 0.61).</div></div><div><h3>Conclusion</h3><div>Local SBRT was associated with trends in improved progression-free survival among patients with oligometastatic head and neck cancer. Prospective studies with larger datasets are warranted to further evaluate the role of this modality in this setting.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100707"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143146694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of probiotics on oral cancer: Mechanistic insights and therapeutic strategies 益生菌对口腔癌的影响：机制见解和治疗策略

Oral Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-01-27 DOI: 10.1016/j.oor.2025.100715

K.S. Lekshmi Priya, Datchanamoorthy Maheswary, Sujith Sri Surya Ravi, Kakithakara Vajravelu Leela, Rahul Harikumar Lathakumari, G. Malavika

{"title":"The impact of probiotics on oral cancer: Mechanistic insights and therapeutic strategies","authors":"K.S. Lekshmi Priya, Datchanamoorthy Maheswary, Sujith Sri Surya Ravi, Kakithakara Vajravelu Leela, Rahul Harikumar Lathakumari, G. Malavika","doi":"10.1016/j.oor.2025.100715","DOIUrl":"10.1016/j.oor.2025.100715","url":null,"abstract":"<div><div>Oral cancer, especially oral squamous cell carcinoma (OSCC), represents a major global health concern, with its notable increase in incidence, especially among younger populations. The disease is multifactorial, with risk factors including tobacco and alcohol use, chronic inflammation, and dysbiosis of the oral microbiome. Probiotics, which are live microorganisms that provide health benefits, have gained attention as a potential approach for modulating the oral microbiome and reducing the risk of oral cancer. This review examines the mechanisms through which probiotics demonstrate anticancer properties, such as binding to and breaking down mutagenic substances, reducing gut pH via the production of short-chain fatty acids, and strengthening the immune response of the host. Specific probiotic strains, such as <em>Lactobacillus</em> and <em>Bifidobacterium</em>, have demonstrated potential in managing oral cancer and its treatment-related complications, such as oral mucositis. Clinical trials suggest that probiotics could act as valuable complementary agents to conventional cancer treatments, enhancing patient outcomes and quality of life. Despite the promising findings, challenges remain in standardizing probiotic formulations and understanding strain-specific effects. Future research should focus on personalized probiotic therapies and innovative delivery systems to enhance their efficacy in oral cancer management. This narrative review emphasizes the potential of probiotics in the prevention and management of oral cancer, showcasing their contribution to oral health and their utility as biomarkers for early diagnosis.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100715"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143146693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to “The application of ChatGPT in the peer-reviewing process” 对“ChatGPT在同行评审过程中的应用”的回应

Oral Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-01-02 DOI: 10.1016/j.oor.2024.100709

Dag Øivind Madsen, Shahab Saquib Sohail

引用次数: 0

Post-translational regulation of stemness under DNA damage response contributes to the gingivobuccal oral squamous cell carcinoma relapse and progression DNA损伤应答下干性的翻译后调控参与了龈颊口腔鳞状细胞癌的复发和进展

Oral Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-15 DOI: 10.1016/j.oor.2025.100730

Sachendra Kumar , Annapoorni Rangarajan , Debnath Pal

{"title":"Post-translational regulation of stemness under DNA damage response contributes to the gingivobuccal oral squamous cell carcinoma relapse and progression","authors":"Sachendra Kumar , Annapoorni Rangarajan , Debnath Pal","doi":"10.1016/j.oor.2025.100730","DOIUrl":"10.1016/j.oor.2025.100730","url":null,"abstract":"<div><div>Tobacco consumption (smoking and specifically smokeless form) in India contributes to a high prevalence of gingivobuccal oral squamous cell carcinoma (OSCC-GB). OSCC-GB exhibits high rates of locoregional relapse and therapeutic resistance, often attributed to the involvement of cancer stem cells (CSCs). The goal of this study is to leverage the generalizability of the machine learning prediction model for ‘Tumor Status’ for a comparative somatic mutation analysis between ‘With Tumor’ (recurred/relapsed/progressed) and ‘Tumor Free’ (disease-free/complete remission) OSCC-GB patients. Our results showed that support vector machines (SVM) classified the ‘Tumor Status’ classes at a mean accuracy of 89% based on clinical features. Furthermore, RNA-seq based somatic mutation analysis using the classified groups revealed molecular mechanisms underlying tumor progression and remission within OSCC-GB subgroups. The identified mutational signature (C>T mutations) related to DNA damage indicates the influence of tobacco-related carcinogens in OSCC-GB subgroups. The analysis of distinct somatic variants, functional impact predictions, protein-protein interactions, and survival analysis highlights the involvement of DNA damage response (DDR)-related genes in ‘With Tumor’, with particular focus on the significant role of the Mitogen-activated protein kinase associated protein 1 (MAPKAP1) gene, a key player in the mTORC2 signaling pathway. The study indicates that loss-of-function in the identified MAPKAP1 somatic variant may promote stemness and elevated risk of relapse and disease progression in OSCC-GB under conditions of DDR in ‘With Tumor’ OSCC-GB, potentially contributing to increased mortality rates among Indian OSCC-GB patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100730"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143480108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In response to Fiorillo: Agreeing on the need to rethink the demonization of AI writing tools such as ChatGPT 作为对Fiorillo的回应：同意有必要重新考虑对ChatGPT等人工智能写作工具的妖魔化

Oral Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-01-07 DOI: 10.1016/j.oor.2024.100712

Dag Øivind Madsen, Shahab Saquib Sohail

引用次数: 0